ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2007
The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 67 citations in OpenAlex.
- Trial
- Article
- Rifampicin-induced challenges in managing endocrine hypertension and primary aldosteronism: a case report and literature review.Frontiers in pharmacology · 2025Article
- Impact of bariatric surgery on cytochrome P 450 enzyme activity.Frontiers in pharmacology · 2024Review
- Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.International journal of molecular sciences · 2023Review
- Interactions of Mycotoxin Alternariol with Cytochrome P450 Enzymes and OATP Transporters.Metabolites · 2022Article
- Article
- Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.Drug design, development and therapy · 2020Review
- Caver Web 1.0: identification of tunnels and channels in proteins and analysis of ligand transport.Nucleic acids research · 2019Article
- Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies.Melanoma management · 2018Review
- Mechanisms and the clinical relevance of complex drug-drug interactions.Clinical pharmacology : advances and applications · 2018Review
- Membrane Fluidity Modulates Thermal Stability and Ligand Binding of Cytochrome P4503A4 in Lipid Nanodiscs.Biochemistry · 2016Article
- Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro.Chinese medicine · 2016Article
- Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study.International journal of clinical pharmacy · 2015Observational
- High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.The pharmacogenomics journal · 2015Article
- How are Interactions Taken into Account in Studies on Conventional and Complementary Therapies for Breast Cancer Patients with Menopausal Complaints?Geburtshilfe und Frauenheilkunde · 2012Article
- Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany.Drug safety · 2012Article
- Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus.Molecular pharmaceutics · 2011Article
- Practical application of toxicogenomics for profiling toxicant-induced biological perturbations.International journal of molecular sciences · 2010Review
- Methadone initiation and rotation in the outpatient setting for patients with cancer pain.Cancer · 2010Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdverse drug interactions are major causes of morbidity, hospitalizations, and mortality. The greatest risk of drug interactions occurs through in the cytochrome system. CYP3A4, the most prevalent cytochrome, accounts for 30-50% of drugs metabolized through type I enzymes. MATERIALS AND
methodsPalliative patients received medications for symptoms and co-morbidities, many of which are substrate, inhibitors, or promoters of CYP3A4 activity and expression. A literature review on CYP3A4 was performed pertinent to palliative medicine. DISCUSSION: In this state of the art review, we discuss the CYP3A4 genetics, and kinetics and common medications, which are substrates or inhibitor/promoters of CYP3A4.
conclusionWe made some recommendations for drug choices to avoid clinically important drug interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.